1. Home
  2. FUND vs ALDX Comparison

FUND vs ALDX Comparison

Compare FUND & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FUND

Sprott Focus Trust Inc.

N/A

Current Price

$9.77

Market Cap

297.6M

Sector

Finance

ML Signal

N/A

Logo Aldeyra Therapeutics Inc.

ALDX

Aldeyra Therapeutics Inc.

N/A

Current Price

$5.05

Market Cap

317.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FUND
ALDX
Founded
1988
2004
Country
Canada
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
297.6M
317.7M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
FUND
ALDX
Price
$9.77
$5.05
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$9.50
AVG Volume (30 Days)
34.1K
902.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
6.64%
N/A
EPS Growth
N/A
40.43
EPS
0.93
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$123.43
P/E Ratio
$10.44
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.21
$1.18
52 Week High
$10.16
$7.14

Technical Indicators

Market Signals
Indicator
FUND
ALDX
Relative Strength Index (RSI) 48.47 47.69
Support Level $8.08 $4.74
Resistance Level $9.96 $5.70
Average True Range (ATR) 0.14 0.37
MACD -0.06 -0.04
Stochastic Oscillator 23.80 48.00

Price Performance

Historical Comparison
FUND
ALDX

About FUND Sprott Focus Trust Inc.

Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, The Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.

About ALDX Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Share on Social Networks: